Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research centre is evaluating innovative treatments aimed at reducing cardiovascular risk in patients with atherosclerotic cardiovascular disease and related conditions.
- Atherosclerosis and cardiovascular disease
- Chronic kidney disease with systemic inflammation
- Major adverse cardiovascular events in high‑risk diabetes
Trials focus on improving survival, lowering blood pressure, and preventing heart attacks through novel antibodies and oral agents.
Immune System Disorders
Studies target inflammatory skin and airway conditions, testing next‑generation biologics for moderate‑to‑severe plaque psoriasis and related diseases.
- Atopic dermatitis
- Moderate‑to‑severe plaque psoriasis
- Psoriatic arthritis (axial and peripheral)
- Severe eosinophilic asthma
The goal is to assess efficacy, safety, and optimal dosing of IL‑23, IL‑17, and JAK pathway inhibitors.
Cancer Research
The site conducts trials in solid tumours, exploring immunotherapy combinations for non‑small cell lung cancer and breast cancer subtypes.
- Advanced non‑small cell lung cancer (NSCLC)
- Triple‑negative breast cancer
- Hormone‑receptor‑positive, HER2‑negative early breast cancer
- Metastatic NSCLC without actionable mutations
Objectives include extending progression‑free survival and overall survival by adding novel antibodies to standard chemotherapy.
Nervous System Disorders
Research addresses neuropathic pain associated with metabolic disease, evaluating new agents for diabetic peripheral neuropathy.
- Diabetic peripheral neuropathic pain
Trials measure pain intensity reduction and long‑term tolerability of emerging analgesic compounds.
Metabolic & Nutritional Health
Multiple studies target obesity and glucose regulation, testing oral and injectable therapies for type 2 diabetes and weight management.
- Type 2 diabetes mellitus
- Obesity and overweight
- Chronic weight management
- Glycemic control in patients on SGLT2 inhibitors
The aim is to achieve better HbA1c reduction, significant weight loss, and lower cardiovascular risk with new drug combinations.
Respiratory Diseases
A focused programme investigates biologic therapies for severe asthma, particularly the eosinophilic phenotype.
- Severe eosinophilic asthma
Objectives include assessing long‑term safety and reduction in exacerbations when added to standard inhaled treatments.
Dermatology & Connective Tissue
The centre evaluates dose‑adjusted regimens for skin‑focused immune diseases, such as moderate‑to‑severe atopic dermatitis.
- Moderate‑to‑severe atopic dermatitis
- Plaque psoriasis
- Psoriatic arthritis
Studies compare new monoclonal antibodies and oral JAK inhibitors to improve skin clearance and joint symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AstraZeneca AB4active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
lock Showing 1 of 50 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2020-11-25 | 2026-07-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.